Recap: Cara Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) reported Q4 earnings with an EPS of $-0.59, missing estimates by -44.0% and a revenue decrease of $257 thousand from the previous year. The company's past earnings performance shows a pattern of not meeting EPS estimates, which previously led to a 7% drop in share price.
March 04, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics reported a significant miss in Q4 earnings with a -44.0% deviation from estimated EPS and a year-over-year revenue decrease.
The significant miss in both EPS and revenue, combined with historical data showing a 7% drop in share price following past earnings misses, suggests a likely negative short-term impact on CARA's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100